Risdiplam
Evrysdi (risdiplam) is a small molecule pharmaceutical. Risdiplam was first approved as Evrysdi on 2020-08-07. It has been approved in Europe to treat spinal muscular atrophy. Evrysdi's patents are valid until 2035-05-11 (FDA).
| Trade Name | Evrysdi |
|---|---|
| Common Name | Risdiplam |
| Indication | spinal muscular atrophy |
| Drug Class | Survival motor neurin SMN1 and SMN2 splicing modulators |
